P230 Development of a Japanese version of the IBD Self-Efficacy Scale and evaluation of its current status in Japan

Tanaka, M.(1);Kawakami, A.(1);Sakagami, K.(2);Terai, T.(3);Ito, H.(4);

(1)Tokyo Medical and Dental University TMDU- Graduate School of Health Care Sciences-, Dep.Critical and Invasive-Palliative Care Nursing, Tokyo, Japan;(2)Kinshukai Infusion Clinic, Dep. of Gastroenterology, Osaka, Japan;(3)Takeda Pharmaceutical Company Limited, Japan Medical Office, Tokyo, Japan;(4)Kinshukai Infusion Clinic, Dept. of Gastroenterology, Osaka, Japan


In chronic diseases like inflammatory bowel disease (IBD), self-efficacy is one of important health outcomes. The IBD-Self-Efficacy Scale (IBD-SES) is an outcome measure used in research settings. In this study, we aimed to develop a Japanese version of IBD-SES and investigate the self-efficacy of IBD patients in Japan.


We conducted a questionnaire survey with IBD patients from two different sources: outpatients of a specialized IBD clinic and respondents recruited online. The original 29-item IBD-SES, with scores from 1 (not at all) to 10 (totally) in each item, and higher scores indicating greater self-management efficacy, was translated into Japanese with permission of the original author and was used for the surveys after confirming its linguistic equivalence with the original version. The reliability of the scale was assessed by calculating the Cronbach's alpha coefficient for internal consistency, and the validity was assessed by disease activity (remission vs. active period) for known-group validity. Items of IBD-SES score comparison between the outpatient clinic group and online  group were performed by t-test.


A total of 919 valid responses were obtained, 482 patients (ulcerative colitis (UC): 184, Crohn's disease (CD): 298) from the specialized IBD clinic and 437 (UC: 255, CD: 182) online. The mean score per item for each subscale [Stress & Emotion Management], [Outpatient care & medication management], [Symptom & disease management] and [Maintenance of remission] was 4.7, 7.3, 4.9, and 4.9, respectively. Internal consistency was confirmed on each subscale (Cronbach’s α: 0.85-0.94). Comparing remission and active periods, significant differences were observed in three subscales: [Stress & Emotion Management (p < 0.001)], [Symptom & disease management (p < 0.001)] and [Maintenance of remission (p < 0.001)], and the known group validity was mostly confirmed.


This study demonstrates the reliability and validity of the Japanese version of the IBD-SES and reveals the current status of self-efficacy of the self-management of IBD patients in Japan. Compared to previous studies using IBD-SES in the USA or Canada, scores observed with Japanese IBD patients are lower. It might reflect a cultural difference.